Alpha 2.0
Login Register
» Articles » PMID: 8554983

Oestrogen Receptor: a Stable Phenotype in Breast Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 1996 Jan 1
PMID 8554983
Citations 25
Authors
J F Robertson
Affiliations
Soon will be listed here.
Abstract

Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may be changed in ER status from positive to negative. This paper proposes an alternative hypothesis that ER expression in a stable phenotype in breast cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.

Citing Articles

Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions.

Cavaleri F, Chattopadhyay S, Palsule V, Kar P, Chatterjee R Integr Cancer Ther. 2024; 23:15347354231223499.

PMID: 38281118 PMC: 10823841. DOI: 10.1177/15347354231223499.

Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.

Kastrati I, Semina S, Gordon B, Smart E Mol Cell Endocrinol. 2019; 483:97-101.

PMID: 30659843 PMC: 6368394. DOI: 10.1016/j.mce.2019.01.014.

Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.

Feldt M, Bjarnadottir O, Kimbung S, Jirstrom K, Bendahl P, Veerla S J Transl Med. 2015; 13:133.

PMID: 25925673 PMC: 4424530. DOI: 10.1186/s12967-015-0486-0.

Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.

Moerkens M, Zhang Y, Wester L, van de Water B, Meerman J BMC Cancer. 2014; 14:283.

PMID: 24758408 PMC: 4021213. DOI: 10.1186/1471-2407-14-283.

Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.

Wei C, Cao Y, Yang X, Zheng Z, Guan K, Wang Q Proc Natl Acad Sci U S A. 2014; 111(5):E601-10.

PMID: 24449872 PMC: 3918824. DOI: 10.1073/pnas.1316255111.

References
1.
Giri D, Dundas S, Nottingham J, Underwood J . Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989; 15(6):575-84. DOI: 10.1111/j.1365-2559.1989.tb01623.x. View
2.
Malafa M, Chaudhuri B, Thomford N, Chaudhuri P . Estrogen receptors in ductal carcinoma in situ of breast. Am Surg. 1990; 56(7):436-9. View
3.
Daly R, Darbre P . Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res. 1990; 50(18):5868-75. View
4.
Murphy C, Pink J, Jordan V . Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 1990; 50(22):7285-92. View
5.
Fuqua S, Fitzgerald S, Chamness G, Tandon A, McDonnell D, Nawaz Z . Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991; 51(1):105-9. View